A
collaborative study led by Yale researchers reports the many gene expression
changes that develop over the course of a neurodegenerative disorder called
spinocerebellar ataxia type 1, shedding light on its progression.
Spinocerebellar ataxia type 1 is a disorder that mainly affects the cerebellum, a brain region involved in motor coordination. With time, patients lose their ability to walk properly.
What is Ataxia?
Ataxia is a degenerative disease of the nervous system. Many symptoms of
Ataxia mimic those of being drunk, such as slurred speech, stumbling, falling,
and incoordination. These symptoms are caused by damage to the cerebellum, the
part of the brain that is responsible for coordinating movement. Ataxia
treatment involves a combination of medication to treat symptoms and
therapy to improve quality of life.
People affected by Ataxia may experience problems with using their fingers and hands, arms, legs, walking, speaking or moving their eyes. Ataxia affects people of all ages. Age of symptom-onset can vary widely, from childhood to late-adulthood. Complications from the disease are serious and oftentimes debilitating. Some types of Ataxia can lead to an early death.
Know more: https://www.ataxia.org/what-is-ataxia/
Most studies of ataxia focus on Purkinje cells, a cell type in the
cerebellum that eventually degenerate and die. However, many other cell types
co-exist in the cerebellum, and their involvement in ataxia is unknown.
Historically, it has been hard to study them, mostly because of their relative
low abundance: to detect their role in a sea of other cells, a cutting-edge,
single-cell approach was needed.
In
a study published
in Neuron on November
27, the Lim lab and collaborators showed that many different cell types are
affected by the disease by using a technique called single-nucleus RNA
sequencing, which allowed them to observe gene expression changes at the level
of individual cells.
Until now, researchers have looked at the cerebellum at the very end of the
disease progression. But what leads to the final stage?
“Here, we
catalog how different cell types are affected from early to late stages of the
disease” said Leon Tejwani, PhD, former
graduate student in Yale’s Interdepartmental Neuroscience Program and co-first
author of the study. The longitudinal study revealed important dysfunctions for
previously unappreciated cerebellar cell types in ataxia.
The team applied a deep learning method to predict if cells were healthy or
not. With this approach, the team was not only able to detect the cells that
exhibit early signs of the disease in the cerebellum, but also identify the
gene expression patterns used by the model to make predictions.
The Yale researchers are the first to study gene expression changes in
post-mortem tissues of patients with ataxia at a single-cell resolution.
Tejwani emphasized how crucial the many collaborations (within Yale and beyond)
were to overcome the limitations, from human post-mortem tissue collection to
single-cell RNA sequencing analysis.
Our study describes what’s going wrong in all cell types of the cerebellum
over the course of the disease, and studying the exact implications of these
dysfunctions – and their overall contributions to the disease – will be the
next step.Leon Tejwani, PhD
While being cautiously conservative for clinical implications, the team
thinks this study will accelerate research in the field of ataxia by being a
resource for labs around the world.
No comments:
Post a Comment